Structural basis of peptide recognition by the angiotensin-1 converting enzyme homologue AnCE from Drosophila melanogaster

Mohd Akif, Geoffrey Masuyer, Richard J. Bingham, Edward D. Sturrock, R. Elwyn Isaac and K. Ravi Acharya

Department of Biology and Biochemistry, University of Bath, UK
Faculty of Biological Sciences, School of Biology, University of Leeds, UK
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa

Keywords
angiotensin-1 converting enzyme; crystal structure; kinetics; natural peptides; substrate recognition

Correspondence
R. Elwyn Isaac, School of Biology, Faculty of Biological Sciences, Clarendon Way, University of Leeds, Leeds LS2 9JT, UK
Fax: +44 1133 432903
Tel: +44 1133 432835
E-mail: R.E.Isaac@leeds.ac.uk

K. Ravi Acharya, Department of Biology and Biochemistry, University of Bath, Claverton Down, Bath BA2 7AY, UK
Fax: +44 1225 386779
Tel: +44 1225 386238
E-mail: bssskra@bath.ac.uk

Present address
*Department of Biochemistry, University of Hyderabad, India
†Department of Biological Sciences, University of Huddersfield, UK

(Received 6 August 2012, revised 8 October 2012, accepted 17 October 2012)

doi:10.1111/febs.12038

Human somatic angiotensin-1 converting enzyme (ACE) is a zinc-dependent exopeptidase, that catalyses the conversion of the decapeptide angiotensin I to the octapeptide angiotensin II, by removing a C-terminal dipeptide. It is the principal component of the renin-angiotensin–aldosterone system that regulates blood pressure. Hence it is an important therapeutic target for the treatment of hypertension and cardiovascular disorders. Here, we report the structures of an ACE homologue from Drosophila melanogaster (AnCE; a proven structural model for the more complex human ACE) co-crystallized with mammalian peptide substrates (bradykinin, Thr6–bradykinin, angiotensin I and a snake venom peptide inhibitor, bradykinin-potentiating peptide-b). The structures determined at 2Å resolution illustrate that both angiotensin II (the cleaved product of angiotensin I by AnCE) and bradykinin-potentiating peptide-b bind in an analogous fashion at the active site of AnCE, but also exhibit significant differences. In addition, the binding of Arg-Pro-Pro, the cleavage product of bradykinin and Thr6–bradykinin, provides additional detail of the general peptide binding in AnCE. Thus the new structures of AnCE complexes presented here improves our understanding of the binding of peptides and the mechanism by which peptides inhibit this family of enzymes.

Database
The atomic coordinates and structure factors for AnCE–Ang II (code 4AA1), AnCE–BPPb (code 4AA2), AnCE–BK (code 4ASQ) and AnCE–Thr6–BK (code 4ASR) complexes have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/)

Structured digital abstract

- **AnCE** cleaves Ang I by enzymatic study (View interaction)
- Bradykinin and **AnCE** bind by x-ray crystallography (View interaction)
- BPP and **AnCE** bind by x-ray crystallography (View interaction)
- **AnCE** cleaves Bradykinin by enzymatic study (View interaction)
- **Ang II** and **AnCE** bind by x-ray crystallography (View interaction)

Abbreviations
ACE, angiotensin-1 converting enzyme; AnCE, an ACE homologue from Drosophila melanogaster; Ang I, angiotensin I; Ang II, angiotensin II; BK, bradykinin; BPPb, bradykinin-potentiating peptide-b from snake venom; HHL, hippuryl–histidyl–leucine.
Introduction

Peptidyl dipeptidase A is a highly glycosylated ectoenzyme that cleaves dipeptides from the C-terminus of a broad range of oligopeptides. The mammalian enzyme is also known as angiotensin-I converting enzyme (ACE; a monomeric, membrane-bound, zinc- and chloride-dependent enzyme, EC 3.4.15.1) after the important role of endothelial ACE in the processing of angiotensin I (Ang I) to angiotensin II (Ang II), a powerful vasoconstrictor [1]. The identification and biochemical characterization of the Ang I convertase led directly to the development of ACE inhibitors that are in widespread clinical use for the treatment of not only hypertension, but also heart failure and other cardiovascular and renal diseases [2-4]. A characteristic that was not appreciated during the development of the first generation of ACE inhibitors was that endothelial (or somatic) ACE comprised two highly similar protein domains (N- and C-domains) linked by a short peptide with each domain possessing a catalytic centre with peptidyl dipeptidase activity. Although both active sites are promiscuous, they display certain substrate preferences [5,6]. In mice, the C-domain is primarily responsible for the in vivo conversion of Ang I to Ang II, whereas bradykinin (BK) is cleaved with similar efficiency by both domains [7,8]. By contrast, the N-domain is solely responsible for the degradation of N-acetyl Ser–Asp–Lys–Pro, a peptide that regulates proliferation of haematopoietic stem cells and fibroblasts [9,10]. The prevention and reversal of fibrosis in the heart, lung and kidney by nonselective ACE inhibitors has been attributed to protection of N-acetyl Ser–Asp–Lys–Pro from degradation in these tissues [11].

The recognition that the two domains have physiological domain-selective substrates has provided the impetus for developing domain-selective inhibitors [4,12,13]. Many ACE inhibitors have low concentration of inhibitor that reduces enzyme activity by 50% (IC₅₀) values for both domains of somatic ACE and this lack of domain specificity has the potential for eliciting side effects resulting from the inhibition of the hydrolysis of bradykinin (BK) and substance-P peptides. There is, therefore, much interest in elucidating the detailed molecular interactions that define domain selectivity in order to provide the basis for structure-based design of ACE inhibitors that selectively target one of the two active sites of mammalian ACE. Substantial information has been gleaned from crystal structures of single-domain forms of human ACE co-crystallized with inhibitors. However, rapid progress in these studies is hindered somewhat by the difficulty in obtaining sufficient protein suitable for crystal growth which necessitates extensive removal of the glycans from the highly glycosylated domains [3,4,12].

These difficulties have been overcome by using a recombinant Drosophila melanogaster ACE (AnCE, a single-domain protein with ACE-like activity) as a suitable model for providing valuable structural information on the interaction between synthetic ACE inhibitors and the enzyme active site. AnCE is a single-domain glycosylated protein that closely shares enzymatic properties with human ACE (in particular the C-domain of human somatic ACE) and is inhibited by classic inhibitors of the human enzymes [14–17]. Importantly, recombinant AnCE expressed in Pichia pastoris readily forms crystals of proteins in complex with inhibitors without the need for removal of sugars [18]. Comparison of the structures of D. melanogaster AnCE with human ACE in complex with the ACE inhibitors captopril and lisinopril confirmed the close similarity in the binding of inhibitors in the active site cleft [18,19].

In this study, we elucidate how the natural peptides Ang II (the principal end-product of the renin-angiotensin-aldosterone system), Arg–Pro–Pro (the BK-derived peptide) and bradykinin-potententiating peptide-b (BPPb, a snake venom inhibitor) bind to the active site of AnCE, revealing novel interactions involving several enzyme subsites. This information will be of value for the understanding of the current and other related Pro-rich peptides as potent inhibitors of AnCE.

Results

Crystal structure of D. melanogaster AnCE-peptide complexes

AnCE was co-crystallized with Ang II, BK, Thr⁵-BK, BPPb and their structures were determined at 2-Å resolution (Fig. 1 and Tables 1 and 2). The co-crystallization of Ang I (Asp–Arg–Val–Tyr–Ile–His–Pro–Phe–His–Leu) with AnCE resulted in conversion to Ang II (Asp–Arg–Val–Tyr–Ile–His–Pro–Phe) which can be observed in the substrate-binding channel. In the AnCE–Ang II peptide complex structure, clear electron density was observed for the tetrapeptide Tyr–Ile–His–Pro (Fig. 2A and Table 2). Ang II is resistant to hydrolysis by AnCE (Fig. S1) and repositions itself in the active site so that the penultimate C-terminal Pro residue shifts from S2 to the S2' subsite after the hydrolysis of Ang I. Based on molecular modelling, we predict that the C-terminal Phe of Ang II could be accommodated in the binding pocket. It is likely that
the side chain of Phe occupies the hydrophobic pocket surrounded by aromatic residues Tyr496, Phe127, Trp263 and Phe169 and the peptide main chain atoms extend into the solvent channel by displacing some of the bound water molecules towards a cluster of polar residues Asp360, Gln266, Asn261 up to Glu269.

Unlike Ang II, BK (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) and Thr\(^6\)-BK (Arg-Pro-Pro-Gly-Phe-Thr-Pro-Phe-Arg) undergo degradation by AnCE to BK(1-3). Strong hydrogen bond interactions with His337 and His497. At the P1 position, the Ile residue is involved in a tetrahedral coordination with the zinc ion and stabilized by a hydrogen bond with Tyr507. The visible electron density terminates at the P2 position with the main chain of Tyr strongly interacting with the main chain of Ala340 (through two hydrogen bonds). The hydroxyl group of Tyr interacts with Thr387 of AnCE.

The detailed structures of AnCE co-crystallized with BK and Thr\(^6\)-BK are presented in Figs 3C,D and S3A, B and exhibit similar mode of binding for the final cleavage product, BK(1-3). Strong hydrogen bond interactions with AnCE anchor the main chain of the N-terminal Arg (P1) at the S1 site (His367, His371 and Tyr507), which is also involved in coordination with the zinc ion. Furthermore, the side chain for this residue is stabilized through contact with Tyr496. Additionally, both structures bind a citrate ion (from the crystallization medium) at the same position, making contact with the N-terminus of the bound BK (1-3) peptide. The citrate ion also interacts directly with the AnCE main chain and the surrounding water molecules. The two Pro residues at positions P1’ and P2’ form a strong interaction with AnCE through hydrogen bonds with residues His497, His337 and Tyr504, Lys495 respectively. The general mode of binding for BK (1-3) appears similar to that of Ang II, particularly through the various hydrogen bonds with AnCE.
Experimental evidence suggests a preferred affinity for Pro at the S2′ binding site and highlights the importance of the hydrophobic pocket (formed by residues Phe441, Phe511, Tyr504, and Tyr507) for peptide recognition, which allows the products of BK and Thr⁶–BK hydrolysis to shift position and ‘register’ in the active site subsites.

The structure of the AnCE–BPPb complex revealed interactions between the pyrrolidine ring of the two Pro residues in the penultimate and C-terminal positions (P1′ and P2′, respectively) and the amino acid side chains that form the S1′ and S2′ enzyme subsites, respectively (Table 3 and Fig. 3E,F). A cluster of aromatic residues forms this binding pocket (Phe441, Phe511, Tyr504, and Tyr507), and Tyr507 ‘stacks’ against the C-terminal Pro, thus enhancing the interaction with AnCE. The two Pro residues (P1′ and P2′) are strongly anchored in the prime binding sites (S1′ and S2′) by hydrogen bonding with multiple residues. The P2′ Pro, in particular, has strong interactions with Gln265, Tyr504 and Lys495. The Ile residue from the BPPb peptide forms a direct coordination with the catalytic zinc ion by replacing the usual water molecule observed in the native AnCE structure [18]. This residue is further stabilized by interaction with the hydroxyl group of Tyr507. The main chain of the next Lys residue of the peptide in the P2 position interacts with Ala340 through two hydrogen bonds. Of the two visible N-terminal residues of BPPb, namely Pro and Arg, Pro is stabilized by hydrophobic interaction with a bulky Trp341 residue, whereas the Arg side chain forms a weak interaction with AnCE via a water-mediated hydrogen bond with Asp501. This part of the structure shows a clear solvent network involving many charged residues and provides room for the accommodation of longer peptide substrates. The homology between AnCE and ACE, and the presence of ‘unique’ N- or C-domain residues provides opportunities for these
subsites to be exploited further for the rational design of new domain-selective ACE inhibitors.

Comparison of the four structures clearly shows a common mode of peptide binding to AnCE. First, the P2′ Pro appears as an essential element in the binding with strong hydrogen bonds and hydrophobic interactions at the S2′ subsite. Second, the backbone interactions at the P1′ and P1 sites are identical in all structures with His337 and His497 stabilizing P1′, and Tyr507 and the zinc ion interacting with the P1 main chain. Finally, Ala340 stabilizes the main chain of P2 when the peptides are visible at that position. This arrangement in the orientation of the peptide backbone makes the P1–P1′ linkage resistant to cleavage.

The common mode of recognition in the four complex structures involves the main chain of the peptide taking control at the catalytic site by replacing a water molecule involved in the proteolysis mechanism. Furthermore, Glu368 (potentially acting as the catalytic base that protonates the amine product) does not seem to be involved in any peptide interaction. Altogether, the peptides presented here show strong interactions with AnCE via their backbone atoms and through direct coordination with the zinc ion, thus preventing proteolysis.

**Ang II is a competitive inhibitor of *D. melanogaster* AnCE**

The crystal structure of AnCE in complex with Ang II provided direct structural evidence for Ang II being a competitive inhibitor of AnCE activity. We sought to confirm this with biochemical data using the synthetic substrate hippuryl–histidyl–leucine (HHL) to assay the peptidyl dipeptidase activity of AnCE. These experiments clearly showed that the hydrolysis of HHL by AnCE was inhibited by Ang II with an IC₅₀ of 58 µM (Fig. 4A) and that Ang II was a competitive inhibitor with a Kᵢ value of 76 µM (Fig. 4B). Consistent with these data, Ang II strongly inhibited the conversion of Ang I to Ang II (73% inhibition) when equimolar concentrations of Ang I and Ang II were incubated with recombinant AnCE (Fig. 4C).

**Discussion**

We report the molecular structures of natural peptides in complex with an AnCE protein. BPPb is one of several blood-pressure-lowering peptides isolated from the venom of *Bothrops jararaca* and has been shown to be an inhibitor of *D. melanogaster* AnCE and both domains of human somatic ACE, but with > 200-fold selectivity towards the C-domain. BPPb is a relatively weak inhibitor of AnCE, displaying a Kᵢ that is one and three orders of magnitude greater than the dissociation constants recorded for the human N-domain and C-domain ACE, respectively. Nevertheless, the structure of AnCE in complex with BPPb has provided detailed molecular information on how the venom peptide inhibits ACE and causes hypotension and shock in envenomated prey. BPPb has a proline as the penultimate C-terminal residue, a feature shared with several other BK-potentiating peptides found in the venom. The cyclic nature of the proline side chain restricts free rotation around the Cα–N bond and the lack of a N–hydrogen bond prevents the formation of H bonds with carbonyls. These structural properties, unique amongst the natural amino acids, protect Ang II and BPPb from peptidase cleavage of the peptide bond that incorporates the amino group of proline [20]. These observations are consistent with the
structural studies of AnCE co-crystallized with BK and Thr<sup>6</sup>–BK. In both cases, complete hydrolysis of the peptide to the end point resulted in clear visible electron density for the tripeptide (Arg–Pro–Pro) in their respective crystal structures. Importantly, the general mode of natural peptide inhibitor binding to AnCE is shared with human ACE. In a recent detailed report [21], we provided the molecular basis for the regulation of human ACE activity by natural inhibitory peptides Ang II and BPPb. In that report, we also highlighted the role of the proline residue, peptide backbone recognition and coordination with the zinc ion in the binding of Ang II to the C-terminal domain of human somatic ACE (Fig. 5A). This might explain the success of clinically used small molecule ACE inhibitors, such as captopril and lisinopril, that are proline derivatives and are able to interact directly with the zinc ion (Fig. 5B,C), thus mimicking the natural peptide inhibitors.

**Drosophila melanogaster** AnCE, like other members of the ACE family in insects, is a highly promiscuous peptidase and converts Ang I to Ang II and inactivates BK, even though these peptides are not found in flies [17]. The broad specificity of the insect enzyme might therefore reflect a general metabolic role for the carboxydipeptidase in peptide metabolism in animals ancestral to the vertebrates before the need for an angiotensin-processing enzyme as part of the renin-angiotensin–aldosterone system. In turn, products of promiscuous proteases often become competing substrates until no more susceptible peptide bonds remain. In the case of Ang II, the proline residue in the penultimate C-terminal position confers resistance to further cleavage by AnCE and mammalian ACE, ensuring that Ang II is the principal product of angiotensinogen metabolism. The Pro at position 7 is also important for binding to the Ang II type 1 (AT<sub>1</sub>) receptor, the principal mediator of Ang II actions in mammals, and is absolutely conserved in all vertebrate Ang II peptides characterized to date [22].

In summary, we have elucidated the molecular interactions that underpin the inhibitory properties of four natural peptides towards AnCE. The work reported here provides new structural information of value in understanding the substrate and inhibitor specificity of the ACE family of peptidases and increasing our understanding of its fascinating evolution from a single- to a two-catalytic-domain enzyme.

### Experimental procedures

All chemicals including BPPb, BK, Thr<sup>6</sup>–BK, Phe-Gly and Ang I peptides were purchased from Sigma-Aldrich (Gillingham, UK). *Drosophila melanogaster* AnCE was generated by

| Table 3. Hydrogen bond interactions of *Drosophila melanogaster* AnCE with Ang II, BK, Thr<sup>6</sup>–BK and BPPb peptides. |
|---|
| Ang II peptide | BPPb peptide | BK peptide | Thr<sup>6</sup>–BK peptide |
| Ligand atom | Interacting atom from AnCE (and Zn ion) | Distance (Å) | Ligand atom | Interacting atom from AnCE (and Zn ion) | Distance (Å) | Ligand atom | Interacting atom from AnCE (and Zn ion) | Distance (Å) |
| Y4 N | A340 O | 3.1 | K3 N | A340 O | 2.9 |
| Y4 O | A340 N | 2.8 | K3 O | A340 N | 2.9 |
| Y4 OH | T387 OG1 | 2.7 |
| I5 O | Y507 OH | 2.7 | I4 O | Y507 OH | 2.6 |
| I5 O | Zinc ion | 2.2 | I4 O | Zinc ion | 2.4 |
| H6 N | A338 O | 3.2 |
| H6 O | H337 NE2 | 2.6 | P5 O | H337 NE2 | 2.8 |
| H6 O | H497 NE2 | 2.9 | P5 O | H497 NE2 | 3.0 |
| P7 O | Y504 OH | 2.6 | P6 O | Y504 OH | 2.6 |
| P7 O | K495 NZ | 2.7 | P6 O | K495 NZ | 2.7 |
| P7 O | Q265 NE2 | 3.2 | P6 O | Q265 NE2 | 3.0 |

| Table 4. Kinetic constants for *Drosophila melanogaster* AnCE. App K<sub>mi</sub>, apparent or observed K<sub>mi</sub>; SE, standard error. |
|---|
| Substrate | Inhibitor | App K<sub>mi</sub> (μM) | K<sub>i</sub> (μM) | SE |
| Ang I | Ang II<sup>b</sup> | 1040<sup>a</sup> | 210 |
| HHL | Abz–YRK(Dnp)P | 75 | 9.6 |
| BPPb | 107 | 14 |

<sup>a</sup> [17].  <sup>b</sup> Ang II was not cleaved by AnCE.
Fig. 3. AnCE–peptide interactions. (A) Ang II-bound AnCE crystal structure. AnCE (cyan), with Ang II in red sticks. The catalytic zinc ion is shown as a green sphere. Bound water molecules as small spheres. (B) Schematic view of Ang II binding. Hydrophobic interactions, hydrogen bonds and distances cited (grey). (C) BK-bound AnCE crystal structure. AnCE (cyan), with BK in pink sticks. Citrate ion in grey. (D) Schematic view of BK binding. Hydrophobic interactions, hydrogen bonds and distances cited (grey). (E) BPPb-bound AnCE crystal structure. AnCE (cyan) with BPPb in orange sticks. (F) Schematic view of BPPb binding. Hydrophobic interactions, hydrogen bonds and distances cited (grey).
expression in *P. pastoris* and purified by hydrophobic interaction chromatography and size-exclusion chromatography to homogeneity, as described previously [18].

**Assay of AnCE activity**

This was determined in a reaction buffer comprising 0.1 M Hepes buffer, pH 7.5, 10 μM ZnSO₄, 0.15 M NaCl and either HHL (5 mM, final concentration) or Ang I (100 μM, final concentration) as the substrate. HPLC with UV-detection (214 nm) was employed to quantify the release of hippuric acid from the hydrolysis of HHL and the conversion of Ang I to Ang II, as described previously [16,23]. When Ang II was tested as an inhibitor of Ang I conversion to Ang II, AnCE activity was measured by comparing the decline in Ang I in the absence and presence of 100 μM Ang II. Recombinant AnCE was diluted in reaction buffer containing 0.1 mg·mL⁻¹ of BSA to give final concentrations of 250 ng·mL⁻¹. To determine the *Kᵢ* of BPPb, AnCE activity

**Fig. 4.** Inhibition of *Drosophila melanogaster* AnCE by Ang II. AnCE was assayed using HHL as substrate in presence of various concentrations of Ang II as described in the Experimental procedures. (A) Data are expressed as a percentage of uninhibited activity and each data point is the mean of three replicates. (B) Lineweaver–Burk plot showing the competitive nature of the inhibition by Ang II of the hydrolysis of HHL by AnCE. (C) The effect of Ang II on the hydrolysis of Ang I (100 μM) by AnCE was determined by quantifying the amount of Ang I consumed in the reaction in the absence and presence of 100 μM Ang II. The results are expressed as % hydrolysis occurring in 30 min and are means ± SEM (n = 4).

**Fig. 5.** Comparison of AnCE–Ang II interactions. (A) Comparison of Ang II binding in AnCE and the C-domain human somatic ACE crystal structures. AnCE (cyan)–Ang II (red) complex superposed with human ACE (pink)–Ang II (green) complex (PDB: 4APH) [21]. The catalytic zinc ion is shown as a green sphere. Residue labels are in black and pink for AnCE and human ACE proteins respectively. (B) Comparison of Ang II and captopril binding in AnCE. AnCE (cyan)–Ang II (red) complex superposed with AnCE–captopril (yellow) complex (PDB: 2X8Z) [18]. (C) Comparison of Ang II and lisinopril binding in AnCE. AnCE (cyan)–Ang II (red) complex superposed with AnCE–lisinopril (grey) complex (PDB: 2X91) [18].
was assayed using Abz-YRK(Dnp)P as substrate, as described by Bingham et al. [17].

X-Ray crystallography

Native AnCE was preincubated with BK, Thr$^6$-BK, BPPb or Ang I peptide (protein/peptide molar ratio of 1 : 14) on ice for 5 h before crystallization. Co-crystals were obtained with 2 µL of the AnCE–peptide sample (10 mg·mL$^{-1}$ in 5 mM Hepes pH 7.5, 0.1 mM phenylmethylsulfonyl fluoride and 10 µM zinc acetate) mixed with an equal volume of reservoir solution (100 mM Hepes pH 7.5 and 1.3 mM sodium citrate) and suspended above the well as a hanging drop. Diffraction-quality crystals of AnCE–peptide complex appeared after ~ 1 week.

X-Ray diffraction data for AnCE–peptide complexes were collected on PX stations IO2 and IO3 at Diamond Light Source (Didcot, UK). No cryoprotectant was used to keep the crystal at constant temperature under the liquid nitrogen jet during data collection. For each complex, 100 images were collected by using a Quantum-4 CCD detector (ADSC Systems, Poway, CA, USA). Raw data images were indexed and scaled using the HKL2000 software package [24]. Data reduction was carried out by using the CCP4 program TRUNCATE [25]. Initial phases for structure solution were obtained using the molecular replacement routines of the Phaser program [26]. The atomic coordinates of native AnCE (PDB: 2X8Y [18]) were used as a search model for AnCE–peptide complexes. The resultant models were refined using REFMAC5 [27]. Five percent of reflections were separated as the free set and used for cross-validation [28]. Manual adjustments of the model were carried out using COOT [29]. Water molecules were added at positions where F$_c$–F$_o$ electron density peaks exceeded 3σ and potential hydrogen bonds could be made. Based on visible electron-density interpretation, BK/Thr$^6$–BK/BPPb/Ang II peptide was incorporated in the structure and further refinement was carried out. Validation was conducted with the aid of MOLPROBITY [30]. There were no residues in the disallowed region of the Ramachandran plot. Crystallographic data statistics are summarized in Table 1. All figures were drawn using Pymol (DeLano Scientific LLC, San Carlos, CA, USA) and rendered with POV-RAY. Hydrogen bonds were verified using HBPLUS [31].

Acknowledgements

We thank the scientists at PX stations IO2 and IO3 at Diamond Light Source, Didcot, Oxon (UK) and Nethaji Thiyagarajan for their support during X-ray diffraction data collection. This work was supported by the Medical Research Council (UK) through a project grant (number G1001685) and a Wellcome Trust (UK) equipment grant (number 088464) to KRA. RJB was in receipt of a Biotechnology and Biological Sciences Research Council (UK) postgraduate studentship.

References

1. Corvol P, Eyries M & Soubrier F (2004) Peptidyl-dipeptidase A/angiotensin I-converting enzyme. In Handbook of Proteolytic Enzymes (Barrett AJ, Rawlings ND & Woessner JF, eds), pp. 332–346. Elsevier Academic Press, San Diego.
2. Ondetti MA & Cushman DW (1982) Enzymes of the renin–angiotensin system and their inhibitors. Annu Rev Biochem 51, 283–308.
3. Acharya KR, Sturrock ED, Riordan JF & Ehlers MR (2003) ACE revisited: a new target for structure-based drug design. Nat Rev Drug Discov 2, 891–902.
4. Anthony CS, Masuyer G, Sturrock ED & Acharya KR (2012) Structure-based drug design of angiotensin-I converting enzyme. Curr Med Chem 19, 845–855.
5. Wei L, Alhenc-Gelas F, Corvol P & Clauser E (1991) The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J Biol Chem 266, 9002–9008.
6. Jaspard E, Wei L & Alhenc-Gelas F (1993) Differences in the properties and enzymatic specificities of the two active sites of angiotensin-I converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem 268, 9496–9503.
7. Fuchs S, Xiao HD, Cole JM, Adams JW, Frenzel K, Michaud A, Zhao H, Keshelava G, Capecchi MR, Corvol P et al. (2004) Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice. J Biol Chem 279, 15946–15953.
8. Fuchs S, Xiao HD, Hubert C, Michaud A, Campbell DJ, Adams JW, Capecchi MR, Corvol P & P (2008) Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension 51, 267–274.
9. Rousseau A, Michaud A, Chauvet MT, Lenfant M & Corvol P (1995) The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J Biol Chem 270, 3656–3661.
10. Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM, Lenfant M, Corvol P & Menard J (1996) Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-erythrosing-proline. J Clin Invest 97, 839–844.
11. Bernstein KE, Shen XZ, Gonzales-Villalobos RA, Billet S, Okwan-Duodu D, Ong FS & Fuchs S (2011) Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme (ACE). Curr Opin Pharmacol 11, 105–111.
12 Watermeyer JM, Kroger WL, Sturrock ED & Ehlers MRW (2009) Angiotensin-converting enzyme – new insights into structure, biological significance and prospects for domain-selective inhibitors. *Curr Enzyme Inhib* 5, 134–147.

13 Douglas RG, Ehlers MRW & Sturrock ED (2011) Vasopeptidase inhibition – solving the cardiovascular puzzle? *Drugs Future* 36, 33–43.

14 Cornell MJ, Williams TA, Lamango NS, Coates D, Corvol P, Soubrier F, Hoheisel J, Lehrach H & Isaac RE (1995) Cloning and expression of an evolutionary conserved single-domain angiotensin converting enzyme from *Drosophila melanogaster*. *J Biol Chem* 270, 13613–13619.

15 Williams TA, Michaud A, Houard X, Chauvet MT, Soubrier F & Corvol P (1996) *Drosophila melanogaster* angiotensin I-converting enzyme expressed in *Pichia pastoris* resembles the C domain of the mammalian homologue and does not require glycosylation for secretion and enzymic activity. *Biochem J* 318, 125–131.

16 Houard X, Williams TA, Michaud A, Dani P, Isaac RE, Shirras AD, Coates D & Corvol P (1998) The *Drosophila melanogaster*-related angiotensin-I-converting enzymes Acer and Anc – distinct enzymic characteristics and alternative expression during pupal development. *Eur J Biochem* 257, 599–606.

17 Bingham RJ, Dive V, Phillips SEV, Shirras AD & Isaac RE (2006) Structural diversity of angiotensin-converting enzyme: insights from structure-activity comparisons of two *Drosophila* enzymes. *FEBS J* 273, 362–373.

18 Akif M, Georgiadis D, Mahajan A, Dive V, Sturrock ED, Isaac RE & Acharya KR (2010) High-resolution crystal structures of *Drosophila melanogaster* angiotensin-converting enzyme in complex with novel inhibitors and antihypertensive drugs. *J Mol Biol* 400, 502–517.

19 Kim HM, Shin DR, Yoo OJ, Lee H & Lee JO (2003) Crystal structure of *Drosophila* angiotensin I-converting enzyme bound to captopril and lisinopril. *FEBS Lett* 538, 65–70.

20 Yang HY, Erdos EG & Levin Y (1971) Characterization of a dipeptide hydrolase (kininase II: angiotensin I converting enzyme). *J Pharmacol Exp Ther* 177, 291–300.

21 Masuyer G, Schware SLU, Sturrock ED, Isaac RE & Acharya KR (2012) Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides. *Sci Rep* 2, 717. DOI:10.1038/srep00717.

22 Watamabe T, Inoue K & Takei Y (2009) Identification of angiotensinogen genes with unique and variable angiotensin sequences in chondrichthyans. *Gen Comp Endocrinol* 161, 115–122.

23 Lamango NS & Isaac RE (1994) Identification and properties of a dipeptidase I in the house fly, *Musca domestica*, that resembles mammalian angiotensin-converting enzyme. *Biochem J* 299, 651–657.

24 Otwinowski Z & Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. In Methods in Enzymology (Carter CW & Sweet RM, eds), pp. 307–326. Academic Press, New York.

25 Collaborative Computational Project Number 4 (1994) The CCP4 Suite: programs for protein crystallography. *Acta Crystallogr* D50, 760–763.

26 McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC & Read RJ (2007) Phaser crystallographic software. *J Appl Crystallogr* 40, 658–674.

27 Murshudov GN, Vagin AA & Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. *Acta Crystallogr* D53, 240–255.

28 Brünger AT (1992) The free R value: a novel statistical quantity for assessing the accuracy of crystal structures. *Nature* 355, 472–474.

29 Emsley P & Cowtan K (2004) Coot: model-building tools for molecular graphics. *Acta Crystallogr* D60, 2126–2132.

30 Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, Murray LW, Arendall WB, Snoeyink J, Richardson JS et al. (2007) MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. *Nucleic Acids Res* 35, W375–W383.

31 McDonald IK & Thornton JM (1994) Satisfying hydrogen bonding potential in proteins. *J Mol Biol* 238, 777–793.

**Supporting information**

Additional supporting information may be found in the online version of this article at the publisher’s web site:

**Fig. S1.** The conversion of Ang I to Ang II (A, B) and the stability of Ang II (C, D) in the presence of recombinant AnCE.

**Fig. S2.** Sequential cleavage of Thr6–BK by AnCE.

**Fig. S3.** (A) Thr6–BK-bound AnCE crystal structure. AnCE (cyan), with Thr6–BK in magenta sticks. Citrate ion in grey. (B) Schematic view of Thr6–BK. Binding with hydrophobic interactions, hydrogen bonds and distances cited (grey).